Abstract
Evolution of carbohidrated antigen 19-9 levels during neoadjuvant treatment can predict resectability and survival in borderline resectable pancreatic adenocarcinoma
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
